KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables: 2010-2024

Historic Receivables for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $174.1 million.

  • Emergent BioSolutions' Receivables rose 20.14% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $680.2 million, marking a year-over-year decrease of 27.39%. This contributed to the annual value of $174.1 million for FY2024, which is 28.18% down from last year.
  • Per Emergent BioSolutions' latest filing, its Receivables stood at $174.1 million for FY2024, which was down 28.18% from $242.4 million recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Receivables peaked at $330.5 million during FY2021, and registered a low of $174.1 million during FY2024.
  • Moreover, its 3-year median value for Receivables was $216.4 million (2022), whereas its average is $211.0 million.
  • In the last 5 years, Emergent BioSolutions' Receivables rose by 14.32% in 2021 and then plummeted by 34.52% in 2022.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Receivables stood at $289.1 million in 2020, then increased by 14.32% to $330.5 million in 2021, then plummeted by 34.52% to $216.4 million in 2022, then rose by 12.01% to $242.4 million in 2023, then decreased by 28.18% to $174.1 million in 2024.